Stem Cell Therapy - 4
4 .

By: tscmru

See more here:
Stem Cell Therapy - 4 - Video

Recommendation and review posted by simmons

The Power of Unlimited Thinking: Grant Korgan at TEDxYouth@SanDiego 2013
It is human to fall down. The magic happens when we get back up. This inspiring talk by Grant Korgan illuminates the power of our thoughts and how choosing p...

By: TEDxYouth

Read the original here:
The Power of Unlimited Thinking: Grant Korgan at TEDxYouth@SanDiego 2013 - Video

Recommendation and review posted by sam

Growing a heart: Divya Ramamoorthy at TEDxYouth@Austin
The journey of generating heart tissues is riddled with "mad scientist selfies." It is a long journey, full of failure, accompanied by only the occasionalre...

By: TEDxYouth

View original post here:
Growing a heart: Divya Ramamoorthy at TEDxYouth@Austin - Video

Recommendation and review posted by sam

Vetrix BioSIS- Regenerative Medicine
Faster more complete healing is now available to all veterinarians. Applications include: hard to heal wounds, skin closure, gastrointestinal, suture line re...

By: Vetrix

See more here:
Vetrix BioSIS- Regenerative Medicine - Video

Recommendation and review posted by sam

When someone has chronic venous insufficiency, it means that because of faulty valves in their leg veins, oxygen-poor blood isn't able to be pumped back to their heart. The George Washington University's Dr. Narine Sarvazyan has created a possible solution, however a beating "mini heart" that's wrapped around the vein, to help push the blood through.

The mini heart takes the form of a cuff of rhythmically-contracting heart tissue, made by coaxing the patient's own adult stem cells into becoming cardiac cells. When one of those cuffs is placed around a vein, its contractions aid in the unidirectional flow of blood, plus it helps keep the vein from becoming distended. Additionally, because it's grown from the patient's own cells, there's little chance of rejection.

So far, the cuffs have been grown in the lab, where they've also been tested. Soon, however, Sarvazyan hopes to conduct animal trials, in which the cuffs are actually grown on the vein, in the body.

"We are suggesting, for the first time, to use stem cells to create, rather than just repair damaged organs," she said. "We can make a new heart outside of ones own heart, and by placing it in the lower extremities, significantly improve venous blood flow."

Scientists at Germany's Fraunhofer Institute for Manufacturing Engineering and Automation are also working on a treatment for chronic venous insufficiency, although their approach has been to create artificial venous valves that could be used to replace the defective natural ones.

A paper on Sarvazyan's research was recently published in the Journal of Cardiovascular Pharmacology and Therapeutics. One of the mini hearts can be seen beating away, in the video below.

Source: The George Washington University

Read more here:
"Mini hearts" on veins could be used to treat circulatory problems

Recommendation and review posted by Bethany Smith

A Non-Trivial Pursuit of Happiness - David Pearce
http://hedweb.com - The Hedonistic Imperative outlines how genetic engineering and nanotechnology will abolish suffering in all sentient life. The abolitioni...

By: Adam Ford

Read more:
A Non-Trivial Pursuit of Happiness - David Pearce - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering 4
Denne videoen handler om Genetic Engineering 4.

By: Fridos Lunde

Visit link:
Genetic Engineering 4 - Video

Recommendation and review posted by Bethany Smith

21 y/o Natural Bodybuilder - Polska Genetics: Full Chest-Workout - pure Inspiration
Check Out http://www.FitnessRebates.com for Fitness Deals, Affordable Gym Wear, More!

By: Bodybuilding Tips

Read the rest here:
21 y/o Natural Bodybuilder - Polska Genetics: Full Chest-Workout - pure Inspiration - Video

Recommendation and review posted by Bethany Smith

When Drugs Break Bad: Clinical Phenotype and Genetics of Methamphetamine.......
3/19/14 - Medicine Grand Rounds - Stanford School of Medicine Speaker: - Vinicio A. de Jesus Perez, MD, FCCP, FAHA Assistant Professor of Medicine (PCCM), St...

By: Lane Medical Library

Read more:
When Drugs Break Bad: Clinical Phenotype and Genetics of Methamphetamine....... - Video

Recommendation and review posted by Bethany Smith

Genetics Part 9: DNA replication 5
This video describes: Polymerase switching and enzyme processivity, removal of RNA template by Rnase H and FEN1 enzyme.

By: Debalina Mukhopadhyay

Read this article:
Genetics Part 9: DNA replication 5 - Video

Recommendation and review posted by Bethany Smith

Gene Therapy Drug Industry across World- Market Landscape Emerging Trends
Gene Therapy Drug Pipeline Analysis @ http://www.reportsnreports.com/reports/269700-gene-therapy-drug-pipeline-analysis.html Order By 31-Mar-2014 Get 20% D...

By: John Kane

Read this article:
Gene Therapy Drug Industry across World- Market Landscape & Emerging Trends - Video

Recommendation and review posted by Bethany Smith

LAKE MARY, Fla. (WOFL FOX 35 ORLANDO) -

A 26-year-old mother of two is about to embark on a medical journey that could stop her multiple sclerosis in its tracks. The disease, which attacks the central nervous system, affects more than 400,000 Americans.

There is no cure for multiple sclerosis, but Heather Nicole Burke believes the stem cell replacement procedure she is about to undergo could make a big difference.

Burke contacted FOX 35, because she wants others to know that the procedure. When Burke got news that her insurance would cover the still-experimental procedure, "I looked at my phone, and I was like, 'This is real! I'm going to get my life back! I'm going to be OK! I'm going to be able to take care of my children!'"

Burke will soon travel from Florida to Chicago for a multi-step stem cell therapy that could stop her disease from progressing.

Dr. Richard Burt, the chief or immunotherapy at Northwestern Memorial Hospital, and his team will use Burke's stem cells to reset her immune system.

"It generates an immune system that ends up -- in the process of doing that -- developing a tolerance to self which puts the disease in remission," Burt explained.

Burt has been performing the experimental procedure on humans since 2008. He said he sees only seven percent of patients relapse. Burt said he often finds insurance companies are willing to pay for the therapy.

"The majority of the time insurance does pay many of the major carriers pay. Medicare pays. Medicaid in the state of Illinois pays. It's a rare carrier that doesn't pay," Burt said.

Burke said her insurance will cover all of the $150,000 procedure. He called that a bargain, considering she is on 19 medications, one of which costs her insurance company $200,000 each year.

See original here:
Woman to undergo stem cell procedure to treat multiple sclerosis

Recommendation and review posted by simmons

George Washington University (GW) researcher Narine Sarvazyan, Ph.D., has invented a new organ to help return blood flow from veins lacking functional valves. A rhythmically contracting cuff made of cardiac muscle cells surrounds the vein acting as a 'mini heart' to aid blood flow through venous segments. The cuff can be made of a patient's own adult stem cells, eliminating the chance of implant rejection.

"We are suggesting, for the first time, to use stem cells to create, rather than just repair damaged organs," said Sarvazyan, professor of pharmacology and physiology at the GW School of Medicine and Health Sciences. "We can make a new heart outside of one's own heart, and by placing it in the lower extremities, significantly improve venous blood flow."

The novel approach of creating 'mini hearts' may help to solve a chronic widespread disease. Chronic venous insufficiency is one of the most pervasive diseases, particularly in developed countries. Its incidence can reach 20 to 30 percent in people over 50 years of age. It is also responsible for about 2 percent of health care costs in the United States. Additionally, sluggish venous blood flow is an issue for those with diseases such as diabetes, and for those with paralysis or recovering from surgery.

This potential new treatment option, outlined in a recently published paper in the Journal of Cardiovascular Pharmacology and Therapeutics, represents a leap for the tissue engineering field, advancing from organ repair to organ creation. Sarvazyan, together with members of her team, has demonstrated the feasibility of this novel approach in vitro and is currently working toward testing these devices in vivo.

Story Source:

The above story is based on materials provided by George Washington University. Note: Materials may be edited for content and length.

See the article here:
'Mini heart' invented to help return venous blood

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

27-Mar-2014

Contact: Lisa Anderson lisama2@gwu.edu 202-994-3121 George Washington University

WASHINGTON (March 27, 2014) George Washington University (GW) researcher Narine Sarvazyan, Ph.D., has invented a new organ to help return blood flow from veins lacking functional valves. A rhythmically contracting cuff made of cardiac muscle cells surrounds the vein acting as a 'mini heart' to aid blood flow through venous segments. The cuff can be made of a patient's own adult stem cells, eliminating the chance of implant rejection.

"We are suggesting, for the first time, to use stem cells to create, rather than just repair damaged organs," said Sarvazyan, professor of pharmacology and physiology at the GW School of Medicine and Health Sciences. "We can make a new heart outside of one's own heart, and by placing it in the lower extremities, significantly improve venous blood flow."

The novel approach of creating 'mini hearts' may help to solve a chronic widespread disease. Chronic venous insufficiency is one of the most pervasive diseases, particularly in developed countries. Its incidence can reach 20 to 30 percent in people over 50 years of age. It is also responsible for about 2 percent of health care costs in the United States. Additionally, sluggish venous blood flow is an issue for those with diseases such as diabetes, and for those with paralysis or recovering from surgery.

This potential new treatment option, outlined in a recently published paper in the Journal of Cardiovascular Pharmacology and Therapeutics, represents a leap for the tissue engineering field, advancing from organ repair to organ creation. Sarvazyan, together with members of her team, has demonstrated the feasibility of this novel approach in vitro and is currently working toward testing these devices in vivo.

###

The study, titled "Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous Insufficiency," is available at http://cpt.sagepub.com/content/early/2014/01/20/1074248413520343.full.

Media: To interview Dr. Sarvazyan about her research, please contact Lisa Anderson at lisama2@gwu.edu or 202-994-3121.

See the original post:
GW researcher invents 'mini heart' to help return venous blood

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise WASHINGTON (March 27, 2014) George Washington University (GW) researcher Narine Sarvazyan, Ph.D., has invented a new organ to help return blood flow from veins lacking functional valves. A rhythmically contracting cuff made of cardiac muscle cells surrounds the vein acting as a 'mini heart' to aid blood flow through venous segments. The cuff can be made of a patients own adult stem cells, eliminating the chance of implant rejection.

We are suggesting, for the first time, to use stem cells to create, rather than just repair damaged organs, said Sarvazyan, professor of pharmacology and physiology at the GW School of Medicine and Health Sciences. We can make a new heart outside of ones own heart, and by placing it in the lower extremities, significantly improve venous blood flow.

The novel approach of creating mini hearts' may help to solve a chronic widespread disease. Chronic venous insufficiency is one of the most pervasive diseases, particularly in developed countries. Its incidence can reach 20 to 30 percent in people over 50 years of age. It is also responsible for about 2 percent of health care costs in the United States. Additionally, sluggish venous blood flow is an issue for those with diseases such as diabetes, and for those with paralysis or recovering from surgery.

This potential new treatment option, outlined in a recently published paper in the Journal of Cardiovascular Pharmacology and Therapeutics, represents a leap for the tissue engineering field, advancing from organ repair to organ creation. Sarvazyan, together with members of her team, has demonstrated the feasibility of this novel approach in vitro and is currently working toward testing these devices in vivo.

The study, titled Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous Insufficiency, is available at http://cpt.sagepub.com/content/early/2014/01/20/1074248413520343.full.

Media: To interview Dr. Sarvazyan about her research, please contact Lisa Anderson at lisama2@gwu.edu or 202-994-3121.

###

About the GW School of Medicine and Health Sciences:

Visit link:
Researcher Invents 'Mini Heart' to Help Return Venous Blood

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise LOS ANGELES (March 27, 2014) Two Cedars-Sinai Heart Institute physician-researchers have been named recipients of prestigious awards from the American College of Cardiology.

Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and a pioneer in developing cardiac stem cell treatments, will be awarded the 2014 Distinguished Scientist Award (Basic Domain) by the 40,000-member medical society during its 63rd Annual Scientific Session on March 31.

Sumeet Chugh, MD, associate director of the Heart Institute and a leading expert on heart rhythm disorders such as sudden cardiac arrest and atrial fibrillation, is to receive the Simon Dack Award for Outstanding Scholarship in recognition of Chughs contributions to the organizations peer-reviewed medical journals.

Dr. Marbn has earned the prestigious title of Distinguished Scientist by pioneering the development of stem cell treatments that can regenerate healthy heart muscle, said Shlomo Melmed, MD, senior vice president of Academic Affairs, dean of the Cedars-Sinai medical faculty and the Helene A. and Philip E. Hixon Chair in Investigative Medicine. Dr. Chugh is leading the quest to unlock the mysteries of how to prevent sudden cardiac arrest, which is 99 percent fatal. Their work is advancing life-saving treatments for patients all over the world and is a testament to the outstanding work of the Heart Institute.

Using techniques that he invented to isolate and grow stem cells from a patient's own heart tissue, Marbn designed and completed the first-in-human cardiac stem cell trial, called CADUCEUS, funded by the National Institutes of Health. The study was the first to show that stem cell therapy can repair damage to the heart muscle caused by a heart attack. Currently, a new, multicenter stem cell clinical trial called ALLSTAR is measuring the effectiveness of donor heart stem cells in treating heart attack patients.

A native of Cuba, Marbn came to the United States with his parents at age 6 as a political refugee. He earned his bachelor's degree in mathematics from Wilkes College in Pennsylvania, and then attended the Yale University School of Medicine in a combined MD/PhD program. Among the many honors Marbn has received are the Basic Research Prize of the American Heart Association the Research Achievement Award of the International Society for Heart Research, the Gill Heart Institute Award and the Distinguished Scientist Award of the American Heart Association.

Chugh, the Pauline and Harold Price Chair in Cardiac Electrophysiology, is an expert in the performance of radio frequency ablation procedures as well as the use of pacemakers, defibrillators and biventricular devices to correct heart rhythm problems. The author of more than 250 articles and abstracts in professional journals, Chugh initiated and directs the ongoing Oregon Sudden Unexpected Death Study, a large, comprehensive assessment of sudden cardiac arrest in a community of 1 million residents. Chugh leads the World Health Organization panel that is charged with performing a worldwide assessment of heart rhythm disorders for the Global Burden of Disease Study.

After earning his medical degree from Government Medical College Patiala, India, Chugh spent the first year of his internal medicine residency at Tufts Newton Wellesley Hospital in Boston and the next two years at Hennepin County Medical Center in Minneapolis. He completed a fellowship in cardiology at the University of Minnesota and a fellowship in clinical cardiac electrophysiology at Mayo Clinic in Rochester, Minn.

Excerpt from:
Two Cedars-Sinai Heart Institute Physicians Honored by American College of Cardiology

Recommendation and review posted by Bethany Smith

Ontario student Moneet Mann is coming to Surrey in her search for a bone marrow donor. Submitted/Vancouver Desi

MANPREET GREWAL VANCOUVER DESI

Will you marrow me?

A 24-year-old Brampton, Ont. girl is bringing her desperate search for a bone marrow match to Surrey this weekend.

Moneet Mann was studying to be a teacher at Thunder Bays Lakehead University when she was diagnosed with acute myeloid leukemia in October last year.

Although the news has been devastating for her and her family, she has chosen to see the blessing in her early diagnoses. With a stem cell transplant she can get back to her life, her school, her friends and passion to teach children.

But her challenge is that a perfect bone marrow match isnt always available in extreme cases, the odds of a match may be as little as one in 750,000.

Since her diagnosis shes started up her Will You Marrow Me? campaign to hunt for a donor, which will be holding a swabbing event alongside Canadian Blood Services at Surreys Dukh Nivaran Gurdwara on Sunday. Mann is particularly putting the call out to South Asian donors between the ages of 17 to 35.

According to Canadian Blood Services, matching between donor and patient happens on a genetic level. What this means is that if a patient is from a certain ethnic background, their donor is most likely going to be from the same ethnic group.

Doctors consider young men to be optimal donors because stem cells from young men can produce fewer chances of complications post-transplant. Also, men are typically physically bigger than women, so they can produce a greater volume of stem cells for the patient.

Excerpt from:
Ontario student's search for bone marrow donor brings her to Surrey

Recommendation and review posted by Bethany Smith

These neurons derived from stem cells made from the skin of people with bipolar disorder communicated with one another differently than neurons made from the skin of people without bipolar disorder.(Credit: University of Michigan)

Bipolar disorder is known to run in families, but scientists have yet to pinpoint the genes involved. Now they have a powerful new tool in the hunt: stem cells.

In a first-of-its-kind procedure, researchers from the University of Michigan have created stem cells from the skin of people with bipolar disorder, and then coaxed the cells into neurons. This has allowed scientists, for the first time, to directly measure cellular differences between people with bipolar disorder and people without.

In the future the cells could provide a greater understanding of what causes the disease, and allow for the development of personalized medications specific to each patients cells.

The team from Michigan took skin cell samples from 22 people with bipolar disorder and 10 people without the disorder. Under carefully controlled conditions, they coaxed adult skin cells into an embryonic stem cell-like state. These cells, called induced pluripotent stem cells, then had the potential to transform into any type of cell. With further coaxing, the cells became neurons.

This gives us a model that we can use to examine how cells behave as they develop into neurons. Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium, study co-leader Sue OShea said in a news release.

Researchers published their findings Wednesday in the journalTranslational Psychiatry.

The research team discovered intriguing differences between stem cellsand neuronsfrom bipolar individuals and those from healthy people.

For one thing, bipolar stem cells expressed more genes associated with receiving calcium signals in the brain. Calcium signals play an important role in neuron development and function. Therefore, the new findings support the idea that genetic differences expressed early in life may contribute to the development of bipolar disorder later in life.

Once the stem cells turned into neurons, researchers tested how they reacted to lithium, a typical treatment for the disorder. The tests showed that lithium normalized the behavior of neurons from bipolar patients by altering their calcium signalingfurther confirmation that this cellular pathway should be of key interest in future studies of the disease.

View original post here:
Stem Cells Shed Light on Treatments for Bipolar Disorder

Recommendation and review posted by Bethany Smith

Hip/low back arthritis; 1.5yrs later, Sandra #39;s results from stem cell therapy by Dr Harry Adelson
Hip/low back arthritis; 1.5yrs later, Sandra #39;s results from stem cell therapy by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

Continued here:
Hip/low back arthritis; 1.5yrs later, Sandra's results from stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by Bethany Smith

Philadelphia, Pa. (PRWEB) March 27, 2014

The Childrens Hospital of Philadelphia has received Pennsylvania Bios Patient Impact Award along with the University of Pennsylvania for developing an innovative treatment called engineered T cell therapy. Pennsylvania Bio presented the Award at its Annual Dinner and Awards Celebration on March 12. Engineered T cell therapy, also called immunotherapy, reprograms a patients immune system to seek and destroy cancer cells, and has shown promising results for patients with leukemia.

Pennsylvania Bios Patient Impact Award recognizes a medicine, therapy, device or organization that has made a significant contribution to the quality of health care or length of life of patients in 2013. Eligible organizations include medical device, diagnostic, pharmaceutical, biotechnology companies or academic institutions with significant operations in Pennsylvania.

I am humbled and honored to have received this prestigious award, and more importantly, to be part of the scientific team that has developed this innovative T cell therapy treatment, said Stephan Grupp, M.D., Ph.D., director of Translational Research in the Center for Childhood Cancer Research at The Childrens Hospital of Philadelphia, and Professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. In the field of cancer, weve come as far as we can using standard treatments such as chemotherapy and radiation. T cell therapy offers new hope for patients with aggressive leukemia, and we are working hard to harness this novel therapy to cure other types of cancer.

The teams most current results, presented at the American Society of Hematology Annual Meeting in December 2013, are that nearly 90 percent of children and adults 24 out of 27 patients with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed complete responses of cancer after receiving T cell therapy.

A relatively new approach in cancer treatment, this type of immunotherapy relies on T cells, the workhorses of the bodys immune system. When cells become cancerous in specific leukemias such as ALL, and are able to evade regular T cell surveillance, the scientists reprogram T cells to function as specialized cancer hunters. Researchers first extract a patients own T cells and genetically modify them. Using bioengineering techniques, they reprogram each patients T cells into chimeric antigen receptor cells, custom-designed to bind to a protein called CD19 that exists only on the surface of B cells. Next, the engineered cells are returned to the patients body, where they proliferate and then eliminate B cells. Moreover, they persist in the circulation, helping to guard against the cancers recurrence.

The trials, a collaboration between The Childrens Hospital of Philadelphia and the University of Pennsylvania, are overseen by Carl H. June, M.D. as trial Sponsor, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in Penns Abramson Cancer Center.

###

About the Cancer Center at The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia has one of the largest pediatric cancer programs in the United States, which has been top ranked by U.S. News & World Report and Parents Magazine. Its large basic and clinical research programs are particularly strong in pediatric neuro-oncology, neuroblastoma, leukemia and lymphoma, and sarcomas. Of all pediatric institutions, Children's Hospital enrolls the most patients in national clinical trials, working in close collaboration with national organizations such as the Children's Oncology Group. Physicians at Children's Hospital have had pioneering roles in developing international standards for diagnosing and treating neuroblastoma, and in developing programs for survivors of childhood cancer. For more information, visit http://www.chop.edu/cancer.

About The Childrens Hospital of Philadelphia: The Childrens Hospital of Philadelphia was founded in 1855 as the nations first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Childrens Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program receives the highest amount of National Institutes of Health funding among all U.S. childrens hospitals. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Link:
The Childrens Hospital of Philadelphia Honored with Pennsylvania Bios Patient Impact Award

Recommendation and review posted by Bethany Smith

Four years ago, University of Iowa scientists discovered that mutations in the prickle gene in Drosophila were responsible for much more than merely altering the bristles on the fly's body to point them in the wrong direction.

Prompted by a colleague's finding that PRICKLE gene mutations were responsible for triggering a form of epilepsy in humans, John Manak, Ph.D., who led the fly research team, took a closer look at the Drosophila prickle mutants. (PRICKLE refers to the human gene, while prickle is the Drosophila form of the gene.)

Through a series of experiments, Dr. Manak found that flies with prickle mutations had seizures with jerky movements of their wings and leg muscles that closely resembled the myoclonic form of epilepsy that affects patients with mutations in the human version of the gene. During myoclonic epileptic seizures, the patients' muscles involuntarily twitch and jerk.

In a 2011 paper about the discovery, the University of Iowa scientists also reported that valproic acid, the anti-convulsive drug, which has been used to effectively treat myoclonic epilepsy patients with PRICKLE gene mutations, also helped control seizures in the mutated flies. These findings suggested that the pathway responsible for seizures in flies and humans was conserved, and that flies with prickle mutations could now be used to screen new experimental therapeutic agents for this disorder. These experiments are now underway.

The scientists have continued to investigate Drosophila flies with the mutated prickle gene. They determined that the seizure threshold, the amount of electrical stimulation required to induce a seizure, was lower in flies with the prickle mutation than in the normal (control) Drosophila flies of the same age, demonstrating that these flies exhibited a classic characteristic of seizure susceptibility. In addition, muscle recordings after experimentally induced electric shock through the nervous system revealed that spiking activity, a measure of neuronal activity, was higher in the flies with the prickle mutations than in the control flies.

Using a technique that they developed for the study, the researchers also found that ataxia (or uncoordinated gait), which occurs in patients with myoclonic epilepsy, also occurs in flies with the prickle gene mutation. The ataxia was more severe in the Drosophila with two prickle gene mutations than in flies with one prickle gene mutated, suggesting that prickle dosage plays an important role in controlling seizures.

The University of Iowa researchers' most recent studies have identified the basic cellular mechanism that goes awry in the prickle mutant flies, leading to the epilepsy-like seizures, and these data will be presented at the GSA Drosophila Research Conference.

Link to presentation abstract: http://abstracts.genetics-gsa.org/cgi-bin/dros14s/showdetail.pl?absno=14531703

Story Source:

The above story is based on materials provided by Genetics Society of America. Note: Materials may be edited for content and length.

View original post here:
Gene mutations in flies, humans produce similar epilepsy syndromes

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise DALLAS March 28, 2014 UTSouthwestern Medical Center researchers are developing a new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.

Dr. Jerry Shay, Vice Chairman and Professor of Cell Biology at UTSouthwestern, led a three-year study on the effects of irradiation in a lung cancer-susceptible mouse model. When his team looked at gene expression changes in the mice, then applied them to humans with early stage cancer, the results revealed a breakdown of which patients have a high or low chance of survival.

The findings, published online in Clinical Cancer Research, offer insight into helping patients assess treatment risk. Radiation therapy and chemotherapy that can destroy tumors also can damage surrounding healthy tissue. So with an appropriate test, patients could avoid getting additional radiation or chemotherapy treatment they may not need, Dr. Shay said.

This finding could be relevant to the many thousands of individuals affected by these cancers and could prevent unnecessary therapy, said Dr. Shay, Associate Director for Education and Training for the Harold C. Simmons Comprehensive Cancer Center at UTSouthwestern. Were trying to find better prognostic indicators of outcomes so that only patients who will benefit from additional therapy receive it.

Dr. Shays study closely monitored lung cancer development in mice after irradiation. His group found some types of irradiation resulted in an increase in invasive, more malignant tumors. He examined the gene expression changes in mice well before some of them developed advanced cancers. The genes in the mouse that correlated with poor outcomes were then matched with human genes. When Dr. Shays team compared the predictive signatures from the mice with more than 700 human cancer patient signatures, the overall survivability of the patients correlated with his predictive signature in the mice. Thus, the classifier that predicted invasive cancer in mice also predicted poor outcomes in humans.

His study looked at adenocarcinoma, a type of lung cancer in the air sacks that afflicts both smokers and non-smokers. The findings also predicted overall survival in patients with early-stage breast cancer and thus offer the same helpful information to breast cancer patients; however the genes were not predictive of another type of lung cancer, called squamous cell carcinoma. Other types of cancers have yet to be tested.

The American Cancer Society estimates the risk of developing lung cancer to be 1 in 13 for men and 1 in 16 for women, including both smokers and non-smokers. Lung cancer is the second most common cancer in both men and women, accounting for about 13 percent of all new cancers, and about 27 percent of cancer deaths. The American Cancer Society estimates more than 224,210 new cases of lung cancer and nearly 160,000 deaths from lung cancer will occur in 2014. Survival statistics vary depending on the stage of the cancer and when it is diagnosed.

Dr. Shays research is paid for in part by a five-year grant from NASA, which helps fund cancer research due to cancer risks faced by astronauts during space missions. The findings could lead to more individualized care and pave the way to better, more science-based care and decision making, he said.

Visit link:
Gene May Predict if Further Cancer Treatments Are Needed

Recommendation and review posted by Bethany Smith

(PRWEB) March 27, 2014

According to the new market research report, Gene Expression Analysis Market by Technology (DNA Microarray, Real-Time PCR, Next Generation Sequencing), Consumables (DNA Chips, Reagents), Services (Gene Profiling, Bioinformatics, Data Analysis Software) & Applications - Global Forecast to 2018, global gene expression analysis market estimated at $2.6 billion in 2013 and is expected to reach $4.3 billion by 2018, growing at a CAGR of 10.4% from 2013 to 2018.

Browse 72 market data tables and 20 figures spread through 227 pages and in-depth TOC on Gene Expression Analysis Market" - http://www.marketsandmarkets.com/Market-Reports/gene-expression-analysis-market-156613968.html.

Early buyers will receive 10% customization on report.

The Global Gene Expression Analysis Market (2013-2018) analyzes and studies the major market drivers and restraints in North America, Europe, Asia, and the Rest of the World (RoW).

Ask for Free PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=156613968.

The global gene expression analysis market is witnessing a significant growth and will continue to do so in the next five years. The factors contributing to this growth are increased funding scenario worldwide, increased government involvement, developments in research for diseases like cancer, and the use of gene expression in drug discovery and personalized medicine. The Asian region is projected to have the highest growth rate with growth hinged at China, India, and Japan. Apart from Asia, countries such as Turkey, Brazil, and South Africa too have a high projected growth.

Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=156613968.

Over the years, gene expression analysis techniques have evolved significantly and are being widely used in the areas of diagnostics, drug discovery, and treatment of certain diseases. In the past few years, the market has witnessed significant technological advancements, as companies have introduced new products in the market. This technologically driven market has witnessed a large number of offerings by big as well as small companies. In order to be competitive in this market, companies must be focused on delivering superior quality products that are technologically advanced.

Various key growth strategies such as new product launches, acquisitions, expansions, agreements, partnerships, collaborations, and joint ventures were mainly adopted by key players such as QIAGEN N.V. (Netherlands), Agilent Technologies (U.S.), Illumina, Inc. (U.S.), Life Technologies Corporation (U.S.), and Roche Diagnostics Corporation (Switzerland). These players adopted these strategies to increase their market shares. For instance, in October 2013, QIAGEN acquired CLC bio, a leading bioinformatics analysis software provider. This acquisition will position QIAGEN as a leader in next-generation bioinformatics, with a focus on biological analysis and interpretation/reporting. Thus, companies are investing efforts and resources in these strategies to help them gain a competitive advantage in the gene expression analysis market.

Read more:
Gene Expression Analysis Market (Gene Profiling, Bioinformatics, Data Analysis Software) worth $4.3 Billion by 2018 ...

Recommendation and review posted by Bethany Smith

The Hedonistic Imperative - David Pearce
Filmed at the Botanical Gardens in Melbourne Australia http://hedweb.com - The Hedonistic Imperative outlines how genetic engineering and nanotechnology will...

By: Adam Ford

Read the original post:
The Hedonistic Imperative - David Pearce - Video

Recommendation and review posted by Bethany Smith

David Pearce - The Hedonistic Imperative vs The Abolitionist Project The Differences
http://hedweb.com - The Hedonistic Imperative outlines how genetic engineering and nanotechnology will abolish suffering in all sentient life. The abolitioni...

By: Adam Ford

Here is the original post:
David Pearce - The Hedonistic Imperative vs The Abolitionist Project The Differences - Video

Recommendation and review posted by Bethany Smith